

# Designing decentralized clinical trials with a patient-centric approach

Henna Alanko  
Optimapharm/Crown CRO, Bayer  
June 2022

# Understanding patients with decentralized clinical trials



## **Agenda:**

**Part I:** Supporting patient engagement with patient-centricity

**Part II:** Improving clinical trial experience with decentralized clinical trials

# Part I: What is patient centricity?



Putting the **patient first**



Achieving the best experience and outcome



Understanding characteristics



Considering social - and financial - perspectives



Expressing preferences and expectations




**Defining the value of healthcare interventions:**



benefits vs. possible risks

# Initiatives of the patient perspective in clinical trials



# Implementation of patient-centric initiatives



Positive impact on patient`s experience



Effective & sustainable organization



Standardized, quantifiable metrics



Impactful and relative value

**Beneficial activities**

# Part II: Introduction to decentralized clinical trials




Digital methods



Patient-centric solutions




Fully or partly remote activities



Main access to cancer clinical trials in traditional and decentralized model in Finland.


# Transforming the way we run clinical trials

## Improving clinical trials by 2030




A critical part of the Evidence Generating System

## Encouraging and engaging patients





# Factors to consider in the design of decentralized clinical trials

- ❖ Patient population
- ❖ Intervention
- ❖ Outcomes







# Defining the level of remoteness



# Patients' views on remote healthcare 1/2



Health-related data



Safety monitoring



Time and costs



Information change




Suitability



Social encounter

# Patients' views on remote healthcare 2/2



Thank you!

